MedDataX Logo

Gastric Cancer Precursor Lesions (GCPL) Study

NCT ID: NCT03188406

Last Updated: 2020-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-02

Study Completion Date

2020-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Gastric cancer is a leading cause of cancer deaths around the world. This disease is a serious problem in places like East Asia, Central and South America, and Eastern Europe. Researchers want to study the causes of gastric cancer and its precursors. They want to reduce the number of people with stomach cancer.

Objectives:

To learn more about bacteria factors and other causes of gastric cancer. To study potential markers associated with precancerous gastric lesions (intestinal metaplasia).

Eligibility:

Adults ages 40-70 years at certain hospitals in Chile who:

Are going to have upper gastrointestinal endoscopies

OR have stomach cancer and need surgery

Design:

Participants will give gastric tissue samples.

Some participants will donate a portion of the stomach tissue that is removed as part of their clinical care.

Participants will give access to reports of their stomach exam. They will allow researchers to photograph the microscope slides of their tissue samples.

Participants will answer questions. The topics of the questions include:

Age, height, weight

Education

Habits including tobacco and alcohol

Personal and family history of disease

Reproductive history

Diet

Some participants will give blood, urine, saliva, and stool samples. Study staff will collect the blood. They will tell the participants how to collect the other samples themselves.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The burden of gastric adenocarcinoma is unevenly distributed, with several Asian and Latin American countries having particularly high incidence rates. Although chronic infection with Helicobacter pylori is the primary cause of this cancer, environmental and host cofactors modify the course of infection and determine whether infected individuals develop cancer. Due to the lack of adequate screening strategies and consequent late diagnosis, trends in mortality are similar to incidence, making this neoplasia the third leading cause of cancer death worldwide. The International Agency for Research on Cancer predicts that there will be no reduction in gastric cancer cases until at least 2030 due to population growth and aging. H. pylori-related gastric carcinogenesis is a multi-step process and mucosal lesions of intestinal metaplasia (IM) and dysplasia confer increased risk of progression. Therefore, case-control studies of these premalignant lesions may provide insights into cancer etiology and inform risk stratification. In addition, biomarkers to identify high-risk individuals are needed for early detection and curative treatment. Accordingly, we propose a 3-year study of Chilean adults undergoing upper gastrointestinal endoscopy for clinical purposes to identify 600 subjects with advanced premalignant lesions (i.e., incomplete-type IM, complete-type IM with extension to gastric corpus and dysplasia) for informative comparisons with 600 controls with non-atrophic gastritis, a benign histologic change apparent in most H. pylori infected individuals. As an additional case group, 100 individuals with newly diagnosed gastric cancer will be recruited from the same clinics. This multidisciplinary project will simultaneously evaluate bacterial, host and environmental factors towards a better understanding of gastric cancer etiology that may guide future efforts for prevention and control. We will explore risk factors that have been insufficiently studied, such as various hormones, H. pylori genomics, non- H. pylori gastric microbiota, and other parasitic infections. We will also evaluate potential noninvasive screening markers, including pepsinogens, hormones, miRNAs and DNA methylation. Results from this study may lead to improved management recommendations for individuals with advanced IM. Additionally, the resulting biobank of gastric tissue, blood, urine, saliva and stool will enable state-of-the-art molecular assays and serve as a resource for future research in this area.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Metaplasia Gastric Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Gastric Intestinal Metaplasia Epidemiology Risk stratification Helicobacter pylori Precancerous lesions Gastric atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gastric cancer

Patients with clinical or histological diagnosis of stomach cancer

No interventions assigned to this group

Gastric intestinal metaplasia

Patients classified as OLGIM \>0

No interventions assigned to this group

Non-atrophic gastritis

Patients classified as OLGA 0

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Two groups of symptomatic patients aged 40 to 70 years old, who are long term residents of a high gastric cancer risk area:

* Approximately 1300 patients who need upper endoscopy (examination of the lining of the stomach with a flexible tube).
* Approximately 100 patients recently diagnosed with stomach cancer who need surgery as treatment for the disease.

Exclusion Criteria

* Pregnant women
* Children
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

M. Constanza Camargo, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

U.S. National Cancer Institute (NCI)

Alejandro Corvalan, M.D.

Role: PRINCIPAL_INVESTIGATOR

Pontificia Universidad Catolica (Chile)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidad de Concepción

Concepción, , Chile

Site Status

Hospital de Curanilahue

Curanilahue, , Chile

Site Status

Hospital Intercultural

Nueva Imperial, , Chile

Site Status

Hospital de Puerto Montt

Port Montt, , Chile

Site Status

Hospital San Juan de Dios

Santiago, , Chile

Site Status

Pontificia Universidad Catolica

Santiago, , Chile

Site Status

Hospital de Temuco

Temuco, , Chile

Site Status

Hospital de Victoria

Victoria, , Chile

Site Status

Hospital de Villarrica

Villarrica, , Chile

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Chile

References

Explore related publications, articles, or registry entries linked to this study.

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992 Dec 15;52(24):6735-40.

Reference Type BACKGROUND
PMID: 1458460 (View on PubMed)

Gonzalez CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013 Sep 1;133(5):1023-32. doi: 10.1002/ijc.28003. Epub 2013 Feb 5.

Reference Type BACKGROUND
PMID: 23280711 (View on PubMed)

Bonequi P, Meneses-Gonzalez F, Correa P, Rabkin CS, Camargo MC. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control. 2013 Feb;24(2):217-31. doi: 10.1007/s10552-012-0110-z. Epub 2012 Dec 7.

Reference Type BACKGROUND
PMID: 23224270 (View on PubMed)

Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010 Jun;71(7):1150-8. doi: 10.1016/j.gie.2009.12.029. Epub 2010 Apr 9.

Reference Type BACKGROUND
PMID: 20381801 (View on PubMed)

Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008 Aug;40(8):650-8. doi: 10.1016/j.dld.2008.02.030.

Reference Type BACKGROUND
PMID: 18424244 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-C-N094

Identifier Type: -

Identifier Source: secondary_id

999917094

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2020-07070

Identifier Type: -

Identifier Source: org_study_id